FDA’s Transparency Roadmap: What It Means for Clinical Trial Disclosure
By James Greene Key Takeaways The US Food & Drug Administration (FDA) has put public release of Clinical Study Reports on its agenda. For US sponsors, clinical document…
Topic
By James Greene Key Takeaways The US Food & Drug Administration (FDA) has put public release of Clinical Study Reports on its agenda. For US sponsors, clinical document…
CANTON, Mich. (December 9, 2025) – TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced today that it has been granted a utility…
Teams in medical writing are being pulled in every direction. Internal experts see how much pressure that they are under to move faster, improve quality, and manage rising…
Quantitative Risk Analysis (QRA) is a systematic approach that enables researchers to identify, evaluate, and manage risks within the clinical trial process, and clinical trials are a pivotal…
The FDA provided insight into their overall vision for clinical trial transparency last week, announcing a new program to publicly release clinical study reports (CSRs) that accompany drug…
Transparency in clinical trials is continually changing, and to stay on top of the news, TrialAssure brings a bi-weekly round-up of some of the key stories. Stories in…
Transparency in clinical trials is continually changing, and to stay on top of the news, TrialAssure brings a weekly round-up of some of the key stories surrounding disclosures…
Knowing where to submit clinical trial results summaries to is the easy part. What becomes difficult is learning the intricacies and transparency requirements of every clinical trial registry…
Transparency in clinical trials is continually changing, and to stay on top of the news, TrialAssure brings a weekly round-up of some of the key stories surrounding disclosures…
TrialAssure has had a busy year so far in building and maintaining clinical trial transparency software. From launching ANONYMIZE to software updates for REGISTRY 2.5, our organization is…